Maxwell Biosciences, a global health technology firm, has secured $20 million in funding to support FDA clinical trials and AI-based research.
The funds will also help expand the commercialization of Claromers—synthetic molecules that mimic the immune system to target pathogens without harming healthy tissue—in industries like cosmetics and cleaning products.
Collaborations with governments and commercial partners are underway, with initial Claromer-based products aimed at preserving the microbiome and combating bacteria and fungi. Human clinical trials are set for 2026, following preclinical studies showing safety, efficacy, and no bacterial resistance.
KEY QUOTES:
“At Maxwell we are deeply committed to reshaping how the world treats infectious disease—without compromising the microbiome. This round, together with non-dilutive funding, allows us to transition from deep R&D into real-world application with partners, all while finalizing preparations for FDA clinical trials of our Claromer drug candidates.”
Scotch McClure, Founder, CEO & Chairman of Maxwell Biosciences
“We’ve spent years engineering and validating Claromers as a first-in-class platform that is simultaneously potent, stable and biocompatible. The data we’ve generated to date show remarkable activity against infectious pathogens while preserving microbiome health and host cells—something conventional antibiotics often fail to do. This funding helps us toward the next step: human trials and commercial deployment.”
Edward M. Rudnic, Ph.D., COO, Head of R&D at Maxwell Biosciences
